NetworkNewsBreaks – CytoDyn Inc. (CYDY) Enters Definitive Agreement to Acquire ProstaGene, Announces Key Addition to Leadership Team
Biotechnology company CytoDyn Inc. (OTCQB: CYDY) this morning announced its entry into a definitive agreement to acquire privately held ProstaGene, LLC. The company also confirmed that Richard G. Pestell, M.D., Ph.D., M.B.A., F.A.C.P., F.R.A.C.P., founder and CEO of ProstaGene, will join CytoDyn as interim chief medical officer. Following close of the acquisition, which is expected in November, Pestell will transition to the role of chief medical officer. “We are honored to soon have world-renowned cancer researcher Dr. Richard Pestell join CytoDyn as our Chief Medical Officer, with responsibility for leading all PRO 140 programs in non-HIV indications,” Nader Pourhassan, Ph.D., president and CEO of CytoDyn, stated in the news release. “We also have taken this important next step to acquire ProstaGene, which will allow Dr. Pestell to accelerate his CCR5 antagonist research related to cancer. As previously stated, our objective is to evaluate PRO 140 in expanded indications including certain cancers and immunological indications concurrent with advancing our promising HIV programs.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Biotechnology company CytoDyn Inc. (OTCQB: CYDY) this morning announced its entry into a definitive agreement to acquire privately held ProstaGene, LLC. The company also confirmed that Richard G. Pestell, M.D., Ph.D., M.B.A., F.A.C.P., F.R.A.C.P., founder and CEO of ProstaGene, will join CytoDyn as interim chief medical officer. Following close of the acquisition, which is expected in November, Pestell will transition to the role of chief medical officer. “We are honored to soon have world-renowned cancer researcher Dr. Richard Pestell join CytoDyn as our Chief Medical Officer, with responsibility for leading all PRO 140 programs in non-HIV indications,” Nader Pourhassan, Ph.D., president and CEO of CytoDyn, stated in the news release. “We also have taken this important next step to acquire ProstaGene, which will allow Dr. Pestell to accelerate his CCR5 antagonist research related to cancer. As previously stated, our objective is to evaluate PRO 140 in expanded indications including certain cancers and immunological indications concurrent with advancing our promising HIV programs.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
